LR 12

Drug Profile

LR 12

Alternative Names: CardioTREM; LR12; Motrem; TREM-like-transcript-1-derived-peptide

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Inotrem
  • Class Peptides
  • Mechanism of Action Immunomodulators; TREML1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myocardial infarction; Septic shock

Most Recent Events

  • 03 Jul 2017 Phase-I clinical trials in Septic shock in Spain, Belgium (IV) (NCT03158948)
  • 22 May 2017 Inotrem plans a phase II trial for Septic shock in Belgium (NCT03158948)
  • 13 Sep 2016 Inotrem completes the phase I trial in Septic Shock in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top